Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.

Olsen J, Jepsen MR.

Int J Technol Assess Health Care. 2010 Apr;26(2):183-91. doi: 10.1017/S0266462310000085.

PMID:
20392322
2.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
3.

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.

4.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
5.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
6.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
7.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
8.

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM.

Vaccine. 2007 Dec 21;26(1):128-39. Epub 2007 Nov 20.

PMID:
18055075
9.

A multi-type HPV transmission model.

Elbasha EH, Dasbach EJ, Insinga RP.

Bull Math Biol. 2008 Nov;70(8):2126-76. doi: 10.1007/s11538-008-9338-x. Epub 2008 Oct 8.

PMID:
18841421
10.

The cost-effectiveness of male HPV vaccination in the United States.

Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.

Vaccine. 2011 Oct 26;29(46):8443-50. doi: 10.1016/j.vaccine.2011.07.096. Epub 2011 Aug 2.

PMID:
21816193
11.

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Dasbach EJ, Insinga RP, Elbasha EH.

BJOG. 2008 Jul;115(8):947-56. doi: 10.1111/j.1471-0528.2008.01743.x. Epub 2008 May 22.

12.

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M.

Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098. Epub 2008 Aug 22.

PMID:
18723068
13.

Cost-effectiveness of human papilloma virus vaccination in Iceland.

Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.

Acta Obstet Gynecol Scand. 2009;88(12):1411-6. doi: 10.3109/00016340903322750.

PMID:
19900074
14.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

15.

Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.

Kawai K, de Araujo GT, Fonseca M, Pillsbury M, Singhal PK.

BMC Infect Dis. 2012 Oct 9;12:250. doi: 10.1186/1471-2334-12-250.

16.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

17.

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Brisson M, Van de Velde N, De Wals P, Boily MC.

Vaccine. 2007 Jul 20;25(29):5399-408. Epub 2007 May 22.

PMID:
17561316
18.

Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.

Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I.

Int J Technol Assess Health Care. 2009 Apr;25(2):161-70. doi: 10.1017/S0266462309090217.

PMID:
19366497
19.

Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Lee VJ, Tay SK, Teoh YL, Tok MY.

BMC Public Health. 2011 Mar 31;11:203. doi: 10.1186/1471-2458-11-203.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk